all report title image

Chronic Pain Market, By Drug Class (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDS), Anticonvulsants, Antidepressants, and Others), By Indication (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer pain, Migraine, Fibromyalgia, and Others), By Application (Musculoskeletal, Neuropathy, Oncology, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Aug 2024
  • Code : CMI4767
  • Pages :260
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.

Market Dynamics:

Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.

Key features of the study:

- This report provides in-depth analysis of the global chronic pain market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global chronic pain market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market

Detailed Segmentation-

  • By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
    • Opioids
    • Non-steroidal anti-inflammatory drugs (NSAIDS)
    • Anticonvulsants
    • Antidepressants
    • Others
  • By Indication Insights (Revenue, USD Bn, 2019 - 2031)
    • Neuropathic pain
    • Arthritis pain
    • Chronic back pain
    • Cancer pain
    • Migraine
    • Fibromyalgia
    • Others
  •  By Application Insights (Revenue, USD Bn, 2019 - 2031)
    • Musculoskeletal
    • Neuropathy
    • Oncology
    • Others
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Pfizer Inc.
    • Johnson & Johnson
    • GlaxoSmithKline PLC
    • Bayer AG
    • Novartis AG
    • Endo Pharmaceuticals
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Reckitt Benckiser Group plc
    • Medtronic plc
    • AstraZeneca PLC
    • Becton, Dickinson and Company
    • AbbVie Inc.
    • Horizon Therapeutics
    • Mallinckrodt Pharmaceuticals
    • Zynerba Pharmaceuticals
    • Neurocrine Biosciences
    • Sorrento Therapeutics
    • Cypress Pharmaceutical

Detailed Segmentation-

  • By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
    • Opioids
    • Non-steroidal anti-inflammatory drugs (NSAIDS)
    • Anticonvulsants
    • Antidepressants
    • Others
  • By Indication Insights (Revenue, USD Bn, 2019 - 2031)
    • Neuropathic pain
    • Arthritis pain
    • Chronic back pain
    • Cancer pain
    • Migraine
    • Fibromyalgia
    • Others
  •  By Application Insights (Revenue, USD Bn, 2019 - 2031)
    • Musculoskeletal
    • Neuropathy
    • Oncology
    • Others
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.